Temprian Therapeutics
Chicago, US · Founded 2019 · Delaware corporation · 3 employees on LinkedIn · 1 known investors
Temprian Therapeutics is a biopharmaceutical company developing an HSP70i-based immunotherapy for vitiligo. It focuses on advancing a treatment for pigmentation disorders through clinical development.
Founders & leadership
Temprian Therapeutics was founded in 2019 by Isabelle Caroline Le Poole and Caroline Le Poole.
IC
Isabelle Caroline Le PooleCo-founder
CL
Caroline Le PooleinCSO & Co-Founder
SD
Sumeet DagarinCEO
PB
JN
John NielandinChief Innovation Officer
KC
Kettil CedercreutzinBoard Member & Co-Founder
Board
MO
Investors · 1
Reported raises · per SEC filings
Form D private placements$275K disclosed across 1 round · 2019
▶$275KraisedNov 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$275KraisedNov 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kettil CedercreutzExecutive Officer, Director
- Isabelle Caroline Le PooleExecutive Officer, Director
- Offering amount
- $325K
- Amount sold
- $275K
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Temprian Therapeutics do?
- Temprian Therapeutics is a biopharmaceutical company developing an HSP70i-based immunotherapy for vitiligo. It focuses on advancing a treatment for pigmentation disorders through clinical development.
- Who founded Temprian Therapeutics?
- Temprian Therapeutics was founded by Isabelle Caroline Le Poole, Caroline Le Poole in 2019.
- Who are Temprian Therapeutics's investors?
- Temprian Therapeutics's investors include 2Flo Ventures.
- How much funding has Temprian Therapeutics raised?
- Temprian Therapeutics has disclosed $275K raised across 1 round.
- Where is Temprian Therapeutics headquartered?
- Temprian Therapeutics is headquartered in Chicago, US.